Sareum Holdings PLC
("Sareum" or the "Company")
Exercise of Warrants
Cambridge, UK, 24 April 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that it has received notices to exercise certain warrants to subscribe for a total of 924,242 new ordinary shares in the capital of the Company at a price of 12.5 pence per ordinary share ("New Ordinary Shares") for a total consideration to the Company of £115,530.25.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the admission of the 924,242 New Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around 29 April 2025. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Immediately following Admission, the total number of ordinary shares in issue will be 134,411,893 and the total number of voting rights will therefore be 134,411,893, and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
- ENDS-
For further information, please contact:
| Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 ir@sareum.co.uk |
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman |
020 7409 3494 |
| O beron Capital (Joint Broker) Mike Seabrook / Nick Lovering |
020 3179 5300 |
| Hybridan LLP (Joint Broker) Claire Noyce |
020 3764 2341 |
| ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com